糖尿病患者应用瑞格列奈联合艾塞那肽治疗的有效性研究

Study on the Effectiveness of Repaglinide Combined with Exenatide in Treatment of Diabetic Patients

目的:探讨糖尿病患者应用瑞格列奈联合艾塞那肽治疗的有效性及对患者血糖水平的影响。方法:选择2017年4月-2019年4月笔者所在医院收治的糖尿病患者128例作为对象,按照用药的不同分为对照组(n=64)和观察组(n=64)。对照组采用艾塞那肽治疗,观察组在对照组的基础上联合瑞格列奈治疗,治疗后对患者效果进行评估,比较两组血糖相关指标、炎症因子水平变化、胰岛素指标及安全性。结果:治疗后观察组FPG、2 h PG、HbA1c、MAGE及CV水平均低于对照组,差异均有统计学意义(P<0.05);治疗后观察组肿瘤坏死因子-α、白细胞介素-1β及超敏C反应蛋白水平均低于对照组,差异均有统计学意义(P<0.05);治疗后观察组HOMA-IR低于对照组,HOMA-β高于对照组,差异均有统计学意义(P<0.05);治疗后观察组不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论:糖尿病患者应用瑞格列奈联合艾塞那肽治疗控制血糖水平良好,改善患者胰岛素抵抗情况,减轻炎症反应,降低不良反应发生率,具有较高的安全性,值得推广应用。

Objective:To investigate the effectiveness of Repaglinide combined with Exenatide in treatment of diabetic patients and its effect on patients’ blood glucose levels.Method:A total of 128 patients with diabetes treated in the author’s hospital from April 2017 to April 2019 were selected as the subjects and divided into the control group (n=64) and the observation group (n=64) according to different medication.The control group was treated with Exenatide,and the observation group was combined with Repaglinide on the basis of the control group.After treatment,the efficacy of patients was evaluated,and the blood glucose related indexes,changes in inflammatory factors,insulin indexes and safety of the two groups were compared.Result:After treatment,the levels of FPG,2 h PG,HbA1c,MAGE and CV in the observation group were lower than those in the control group,the differences were statistically significant (P<0.05).After treatment,the levels of tumor necrosis factor-α,interleukin-1β and hypersensitive C-reactive protein in the observation group were lower than those in the control group,the differences were statistically significant (P<0.05).After treatment,HOMA-IR in the observation group was lower than that in the control group,and HOMA-β was higher than that in the control group,the differences were statistically significant (P<0.05).After treatment,the incidence of ADR in the observation group was lower than that in the control group,the difference was statistically significant (P<0.05).Conclusion:The treatment of Repaglinide combined with Exenatide in diabetic patients can control blood sugar levels well,improve insulin resistance,reduce inflammation,and reduce the occurrence of adverse reactions.It has high safety and is worthy of popularization and application.